IL2 and cancer: The preclinical data show that while lymphocytes (and particularly CD8+ ones) are the main agents involved in cancer cells killing both directly and through cytokines (e.g., IFN-γ, IL-2, and IL-12), neutrophiles foster a pro-cancer inflammatory microenvironment that inhibits lymphocytes activity via the production of a palette of cytokines (e.g., IL-10, TNF-α, and VEGF) [89,90,91].